InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,455.21
(
0.38%
)
US TECH 100
18,509.20
(
0.00%
)
Dow Jones
40,008.39
(
0.61%
)
Brent Oil
79.63
(
0.01%
)
Bitcoin
57,932.92
(
-1.33%
)
Post# of 252892
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: DewDiligence post# 102745

Friday, 08/27/2010 6:03:59 PM

Friday, August 27, 2010 6:03:59 PM

Post# of 252892

From a practical standpoint, the two phrases mean essentially the same thing.



They actually don't in cases where newer therapies increase tolerability and have higher therapeutic indexes. Proving either is not necessarily a quicker path to approval. The difference between the two phrases is likely to grow over time (couple decades) as pharmacoeconomics works into the equation.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up